People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lipella Pharmaceuticals Inc. | — | Pharmaceuticals | Seed | $8.2M | $9.6M | 2023 |
Naoki Yoshimura at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Naoki Yoshimura on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Cohen | 1 | 15 |
| Jonathan Kaufman | 1 | 3 |
| THOMAS PETZINGER, JR. | 1 | 2 |
| LEAF HUANG | 1 | 2 |
| DAVID BATTLEMAN | 1 | 2 |
| Byong Kim | 1 | 1 |
| Douglas Johnston | 1 | 1 |
| Ryan Pruchnic | 1 | 1 |
| BERNARD TOKARCZYK | 1 | 1 |
| MICHAEL CHANCELLOR | 1 | 1 |
| PRADEEP TYAGI | 1 | 1 |
| Lori Birder | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.